Reviewing Bone Biologics (NASDAQ:BBLG) & Nutriband (NASDAQ:NTRB)

Bone Biologics (NASDAQ:BBLG) and Nutriband (NASDAQ:NTRB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability.

Risk and Volatility

Bone Biologics has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500. Comparatively, Nutriband has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.

Profitability

This table compares Bone Biologics and Nutriband’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bone Biologics	N/A	-236.06%	-154.82%
Nutriband	-252.90%	-73.13%	-57.85%

Earnings and Valuation

This table compares Bone Biologics and Nutriband’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bone Biologics	N/A	N/A	-$8.95 million	($49.68)	-0.03
Nutriband	$2.08 million	17.20	-$4.48 million	($0.67)	-6.82

Nutriband has higher revenue and earnings than Bone Biologics. Nutriband is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 19.7% of Nutriband shares are held by institutional investors. 13.0% of Bone Biologics shares are held by company insiders. Comparatively, 43.2% of Nutriband shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for Bone Biologics and Nutriband, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bone Biologics	0	0	0	0	N/A
Nutriband	0	0	0	0	N/A

Summary

Nutriband beats Bone Biologics on 7 of the 10 factors compared between the two stocks.

About Bone Biologics

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

About Nutriband

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.